Advertisement

Archives of Gynecology and Obstetrics

, Volume 297, Issue 5, pp 1235–1244 | Cite as

Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer

  • Rui-qiong Ma
  • Zhi-jian Tang
  • Xue Ye
  • Hong-yan Cheng
  • Kun-kun Sun
  • Xiao-hong Chang
  • Heng Cui
Gynecologic Oncology

Abstract

Objective

Glycoprotein non-metastatic protein B (GPNMB) is a transmembrane glycoprotein that is expressed at higher levels in several malignant human tissues than those in matched normal tissues. Thus, GPNMB may serve as an attractive therapeutic target of cancer treatment. In this study, the prognostic value of GPNMB expression was examined in tumors derived from a cohort of patients with epithelial ovarian cancer (EOC).

Methods

GPNMB expression in matched formalin-fixed and paraffin-embedded tissue samples was evaluated by immunohistochemistry (IHC), whereas GPNMB mRNA expression in fresh-frozen biopsy tissues was detected using real-time quantitative PCR (qPCR). Meanwhile, the correlations of GPNMB expression with the clinical characteristics of EOC were assessed. Besides, survival data were analysed using Kaplan–Meier and Cox regression analyses, respectively.

Results

GPNMB expression was remarkably upregulated in EOC tissues compared with that in normal ovarian controls at both mRNA and protein levels. In addition, abundant GPNMB expression in EOC was correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage (P < 0.001), residual tumor (P = 0.036), and lymph node metastasis (P = 0.004). Furthermore, results of univariate and multivariate analyses indicated that GPNMB expression level was an independent prognostic factor of the progression-free survival (PFS) and overall survival (OS) (P < 0.001 and P < 0.001, respectively) for EOC patients.

Conclusion

Upregulated GPNMB levels in EOC patients are associated with dismal prognosis. Moreover, findings in the current study indicate that GPNMB is a potentially useful prognostic predictor of the therapeutic approaches for EOC.

Keywords

Epithelial ovarian cancer GPNMB Immunohistochemistry Prognosis 

Notes

Acknowledgements

We thank Dr. Danhua Shen and Dr. Kunkun Sun from Department of Pathology of Peking University People’s Hospital for their helpful advice on pathological assessments. This work is supported by the National Key Research and Development Programme of China (Grant No. 2016YFA0201400) and the National Key Technology R&D Program (Grant No. 2015BAI13B06).

Author contributions

RM is responsible for project development, data analysis and manuscript compiling. ZT and XY are in charge of data collection or management. HC and KS take charge of data analysis. XC and HC are responsible for protocol/project development.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Study involving human participants

Tissues from human participants are adopted in the current study. All procedures performed in studies involving human participants should be in strict accordance with the ethical standards of the Institute Research Ethics Committee of Peking University People’s Hospital as well as the Helsinki declaration (1964) and its later amendments or comparable ethical standards.

Informed consent

Informed consent is obtained from all participants enrolled in the current study.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30.  https://doi.org/10.3322/caac.21166 CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236.  https://doi.org/10.3322/caac.20121 CrossRefPubMedGoogle Scholar
  3. 3.
    Amate P, Huchon C, Dessapt AL et al (2013) Ovarian cancer: sites of recurrence. Int J Gynecol Cancer 23:1590–1596.  https://doi.org/10.1097/IGC.0000000000000007 CrossRefPubMedGoogle Scholar
  4. 4.
    Owen TA, Smock SL, Prakash S et al (2003) Identification and characterization of the genes encoding human and mouse osteoactivin. Crit Rev Eukaryot Gene Expr 13:205–220.  https://doi.org/10.1615/CritRevEukaryotGeneExpr.v13.i24.130 CrossRefPubMedGoogle Scholar
  5. 5.
    Weterman MA, Ajubi N, van Dinter IM et al (1995) nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer 60:73–81.  https://doi.org/10.1002/ijc.2910600111 CrossRefPubMedGoogle Scholar
  6. 6.
    Anderson MG, Smith RS, Hawes NL et al (2002) Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet 30:81–85.  https://doi.org/10.1038/ng794 CrossRefPubMedGoogle Scholar
  7. 7.
    Ripoll VM, Meadows NA, Raggatt LJ et al (2008) Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. Gene 413:32–41.  https://doi.org/10.1016/j.gene.2008.01.014 CrossRefPubMedGoogle Scholar
  8. 8.
    Sheng MH, Wergedal JE, Mohan S et al (2012) Targeted overexpression of osteoactivin in cells of osteoclastic lineage promotes osteoclastic resorption and bone loss in mice. PLoS One 7:e35280.  https://doi.org/10.1371/journal.pone.0035280 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chung JS, Bonkobara M, Tomihari M et al (2009) The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur J Immunol 39:965–974.  https://doi.org/10.1002/eji.200838990 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hoashi T, Sato S, Yamaguchi Y et al (2010) Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. FASEB J 24:1616–1629.  https://doi.org/10.1096/fj.09-151019 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Li B, Castano AP, Hudson TE et al (2010) The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J 24:4767–4781.  https://doi.org/10.1096/fj.10-154757 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Williams MD, Esmaeli B, Soheili A et al (2010) GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res 20:184–190.  https://doi.org/10.1097/CMR.0b013e3283364a08 PubMedGoogle Scholar
  13. 13.
    Zhao Y, Qiao ZG, Shan SJ et al (2012) Expression of glycoprotein non-metastatic melanoma protein B in cutaneous malignant and benign lesions: a tissue microarray study. Chin Med J (Engl) 125:1382–3279.  https://doi.org/10.3760/cma.j.issn.0366-6999.2012.18.015 Google Scholar
  14. 14.
    Rich JN, Shi Q, Hjelmeland M et al (2003) Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278:15951–15957.  https://doi.org/10.1074/jbc.M211498200 CrossRefPubMedGoogle Scholar
  15. 15.
    Tian F, Liu C, Wu Q et al (2013) Upregulation of glycoprotein nonmetastatic B by colony-stimulating factor-1 and epithelial cell adhesion molecule in hepatocellular carcinoma cells. Oncol Res 20:341–350.  https://doi.org/10.3727/096504013X13657689382851 CrossRefPubMedGoogle Scholar
  16. 16.
    Eldai H, Periyasamy S, Al Qarni S et al (2013) Novel genes associated with colorectal cancer are revealed by high resolution cytogenetic analysis in a patient specific manner. PLoS One 8:e76251.  https://doi.org/10.1371/journal.pone.0076251 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kanematsu M, Futamura M, Takata M et al (2015) Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer. Cancer Med 4:1344–1355.  https://doi.org/10.1002/cam4.480 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rose AA, Grosset AA, Dong Z et al (2010) Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 16:2147–2156.  https://doi.org/10.1158/1078-0432.CCR-09-1611 CrossRefPubMedGoogle Scholar
  19. 19.
    Estilo CL, O-charoenrat P, Talbot S et al (2009) Oral tongue cancer gene expression profiling: identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 9:11.  https://doi.org/10.1186/1471-2407-9-11 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tyburczy ME, Kotulska K, Pokarowski P et al (2010) Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. Am J Pathol 176:1878–1890.  https://doi.org/10.2353/ajpath.2010.090950 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Onaga M, Ido A, Hasuike S et al (2003) Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, l-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 39:779–785.  https://doi.org/10.1016/S0168-8278(03)00361-1 CrossRefPubMedGoogle Scholar
  22. 22.
    Prisco MG, Zannoni GF, De Stefano I et al (2012) Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study. Hum Pathol 43:282–288.  https://doi.org/10.1016/j.humpath.2011.05.002 CrossRefPubMedGoogle Scholar
  23. 23.
    Maric G, Rose AA, Annis MG et al (2013) Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther 6:839–852.  https://doi.org/10.2147/OTT.S44906 PubMedPubMedCentralGoogle Scholar
  24. 24.
    Rose AA, Pepin F, Russo C et al (2007) Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 5:1001–1014.  https://doi.org/10.1158/1541-7786.MCR-07-0119 CrossRefPubMedGoogle Scholar
  25. 25.
    Qin C, Liu Z, Yuan Y et al (2014) Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy. Mol Med Rep 9:851–856.  https://doi.org/10.3892/mmr.2014.1896 CrossRefPubMedGoogle Scholar
  26. 26.
    Kuan CT, Wakiya K, Dowell JM et al (2006) Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12:1970–1982.  https://doi.org/10.1158/1078-0432.CCR-05-2797 CrossRefPubMedGoogle Scholar
  27. 27.
    Li YN, Zhang L, Li XL et al (2014) Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer. APMIS 122:140–146.  https://doi.org/10.1111/apm.12107 CrossRefPubMedGoogle Scholar
  28. 28.
    Mokarram P, Kumar K, Brim H et al (2009) Distinct high-profile methylated genes in colorectal cancer. PLoS One 4:e7012.  https://doi.org/10.1371/journal.pone.0007012 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Fiorentini C, Bodei S, Bedussi F et al (2014) GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp Cell Res 323:100–111.  https://doi.org/10.1016/j.yexcr.2014.02.025 CrossRefPubMedGoogle Scholar
  30. 30.
    Tomihari M, Chung JS, Akiyoshi H et al (2010) DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res 70:5778–5787.  https://doi.org/10.1158/0008-5472.CAN-09-2538 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Rose AA, Annis MG, Dong Z et al (2010) ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One 5:e12093.  https://doi.org/10.1371/journal.pone.0012093 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Gynaecology Oncology CenterPeking University People’s HospitalBeijingPeople’s Republic of China
  2. 2.Department of PathologyPeking University People’s HospitalBeijingPeople’s Republic of China

Personalised recommendations